Alnylam Pharmaceuticals at SCOPE 2027

Mar 1–4, 2027 Orlando, FL ~5k attendees Website

Alnylam Pharmaceuticals brings 2 presentations to SCOPE 2027 in Orlando. Its program centers on composite digital measures and growing operations for late-stage trials. The most concrete is scaling teams and talent for Phase 3 and beyond.

OrganizationSCOPE 2027 Attendance
alnylam.com
Biotech
Develops and markets RNA interference medicines for rare and common diseases.
Panel
Tue Mar 2
3:20pm–3:55pm
From Signals to Endpoints: Designing and Scaling Composite and Multimodal Measures across Clinical Development
Digital Measures & eClinical Technologies · with Digital Medicine Society (DiMe), BioMarin Pharmaceutical, Sanofi +1 more
Talk
Wed Mar 3
11:40am–12:05pm
Scaling Operations and Talent for Phase 3 and Beyond
SCOPE Biotech Forum
Outsourcing and budgeting

Explore the full SCOPE 2027 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Orlando. Leave your work email and we’ll be in touch.

Privacy

Download the full SCOPE 2027 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Alnylam Pharmaceuticals

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by SCOPE Summit or its organizers. Submit a correction